Moderna, Inc. (MRNA)
Moderna, Inc. (MRNA) Discusses Intismeran mRNA Immunotherapy and Phase II KEYNOTE-942 Oncology Data Transcript
Moderna, Inc. (MRNA) Discusses Intismeran mRNA Immunotherapy and Phase II KEYNOTE-942 Oncology Data Transcript
Moderna partners with global health coalition to develop Bundibugyo Ebola vaccine
Moderna said on Monday it has partnered with the Coalition for Epidemic Preparedness Innovations to develop a potential vaccine against Bundibugyo ebolavirus, the strain linked to the ongoing Ebola outbreak in eastern Democratic Republic of Congo.
Moderna, Inc. (MRNA) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript
Moderna, Inc. (MRNA) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript
Forget Moderna: This Biotech Juggernaut Is a Way Better Buy Right Now
Moderna (NASDAQ:MRNA | MRNA Price Prediction) is back in the headlines after ripping 63.17% higher year to date on a surprise Q1 revenue triple and renewed pipeline excitement.
Moderna, Inc. (MRNA) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Moderna, Inc. (MRNA) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Moderna, Inc. (MRNA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Moderna, Inc. (MRNA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Moderna's AI Could Get a Hantavirus Vaccine Here Faster
Drug development has always been a slow business. A single medicine can take 10 to 15 years and cost billions before it reaches a patient.
Moderna Says It's Researching a Hantavirus Vaccine. The Drugmaker's Stock Is Surging.
Moderna's stock is rallying on hopes it could develop a hantavirus vaccine.
Here's how much Moderna's stock has rallied off renewed focus on hantavirus research
The public is growing increasingly concerned about the possibility that a hantavirus outbreak on a cruise could spark a new pandemic.
Moderna shares extend gains as hantavirus vaccine work draws attention
Moderna Inc (NASDAQ:MRNA, XETRA:0QF) shares continued to extend recent gains on Monday as investors welcomed reports that the company is researching a hantavirus vaccine and advancing early-stage work in the area. Shares of Moderna have added more than 16% in the last five days, trading hands at about $55.
Moderna Stock Is Up 6% Today: Is It Outperforming Other Vaccine Stocks Like Pfizer and Novavax?
Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) are up roughly 6% in Monday morning trading, changing hands near $57.52 after Friday's close of $54.35.
Moderna stock soars as hantavirus fears spark outbreak trade
Moderna shares surged on Monday as investors rushed into vaccine and biotech stocks following reports of a hantavirus outbreak linked to a cruise ship, despite health authorities maintaining that the overall public health risk remains low. The stock rose 9.43% to $59.48, its intraday high after a US national tested mildly positive for the Andes strain of hantavirus.
